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CRACM/Orai ion channel expression and function in human
lung mast cells
Ian Ashmole, PhD,a* S. Mark Duffy, PhD,a* Mark L. Leyland, PhD,b Valerie S. Morrison, BSc,c Malcolm Begg, PhD,c and
Peter Bradding, DMa Leicester and Stevenage, United KingdomBackground: Influx of extracellular Ca21 into human lung mast
cells (HLMCs) is essential for the FcεRI-dependent release of
preformed granule-derived mediators and newly synthesized
autacoids and cytokines. However, the identity of the ion
channels underlying this Ca21 influx is unknown. The recently
discovered members of the CRACM/Orai ion channel family
that carries the Ca21 release–activated Ca21 current are
candidates.
Objectives: To investigate the expression and function of
CRACM channels in HLMCs.
Methods: CRACM mRNA, protein, and functional expression
were examined in purified HLMCs and isolated human
bronchus.
Results: CRACM1, -2, and -3 mRNA transcripts and CRACM1
and -2 proteins were detectable in HLMCs. A CRACM-like
current was detected following FcεRI-dependent HLMC
activation and also in HLMCs dialyzed with 30 mM inositol
triphosphate. The Ca21-selective current obtained under both
conditions was blocked by 10 mM La31 and Gd31, known
blockers of CRACM channels, and 2 distinct and specific
CRACM-channel blockers—GSK-7975A and Synta-66. Both
blockers reduced FcεRI-dependent Ca21 influx, and 3 mM
GSK-7975A and Synta-66 reduced the release of histamine,
leukotriene C4, and cytokines (IL-5/-8/-13 and TNFa) by up to
50%. Synta-66 also inhibited allergen-dependent bronchial
smooth muscle contraction in ex vivo tissue.
Conclusions: The presence of CRACM channels, a CRACM-like
current, and functional inhibition of HLMC Ca21 influx,
mediator release, and allergen-induced bronchial smooth
muscle contraction by CRACM-channel blockers supports a
role for CRACM channels in FcεRI-dependent HLMC
secretion. CRACM channels are therefore a potential
therapeutic target in the treatment of asthma and related
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Mast cells play a major role in the pathophysiology of asthma
and related allergic diseases such as rhinitis, urticaria, and
anaphylaxis.1 Allergens and many nonimmunological stimuli
activate complex signaling cascades in mast cells that lead to
the secretion of a plethora of autacoid mediators, cytokines,
and proteases.1 Excess release of these mediators contributes
to complex immunopathologies and symptoms. Current putative
clinical inhibitors of human mast cell (MC) mediator release,
such as cromoglycate and b2-adrenoceptor agonists, are ineffec-
tive in some tissues such as the skin,2 and in lung they show
weak activity and/or rapid tachyphylaxis/desensitization to the
effects both in vitro and in vivo.2-5 A novel potent inhibitor of
mast cell secretion that maintains its activity on chronic admin-
istration would therefore be of great benefit for the treatment of
asthma and allergy.
Ion channels are emerging as attractive targets for the func-
tional modulation of inflammatory and structural nonexcitable
cells.6,7 Channels carrying Ca21, K1, and Cl2 regulate diverse
cell processes including secretion,8 proliferation,9 adhesion,10
and migration.11 Influx of extracellular Ca21 is an essential re-
quirement for the IgE-dependent release of both preformed
(granule-derived) mediators and newly generated autacoids and
cytokines from mast cells.12 Receptor-mediated signaling in
many nonexcitable cells including mast cells initiates an initial
rise in intracellular Ca21 because of its release from endoplasmic
reticulum stores. The resulting store depletion induces Ca21 entry
through the plasma membrane, a process termed store-operated
Ca21 entry.13 The Ca21 current passing through the plasma mem-
brane is known as the Ca21 release–activated Ca21 (CRAC) cur-
rent, and it is believed to play a central role in many physiological
processes such as gene transcription, proliferation, and cytokine
release.13,14 The Ca21 release–activated Ca21 current has been
well characterized electrophysiologically in several cells includ-
ing rodent mast cells,15 and the molecular components of the
CRAC channel have been recently identified. STIM1 senses the
endoplasmic reticulum Ca21 concentration and transmits this
information to the CRAC-channel pore.16 CRACM1 (also known
as Orai1) was subsequently identified as the Ca21-selective pore-
forming protein in the plasma membrane.17-20 Mammalian cells
express 2 further homologs—CRACM2 and CRACM321—which
also carry CRAC currents but exhibit distinct functional pro-
perties.21 CRACM1 may form heterodimeric channels with
CRACM2 and CRACM3.21
Studies in a CRACM1 knockout mouse suggested that
CRACM1 function is essential for mast cell degranulation,
leukotriene C4 (LTC4) release, and TNFa production following
IgE-dependent activation, while CRACM2 regulates T-cell re-
sponses.22 However, whether CRACM channels operate in
J ALLERGY CLIN IMMUNOL
VOLUME 129, NUMBER 6
ASHMOLE ET AL 1629Abbreviations used[Ca21]i: Intracellular free Ca
21CRAC: Ca21 release–activated Ca21DMSO: Dimethyl sulfoxideHLMCs: Human lung mast cellsLTC4: Leukotriene C4
MC: Mast cellhuman MCs is not known. Because of the profound differences
between rodent mast cells and human MCs in terms of pharma-
cology, mediator content, immunological responsiveness, and ion
channel expression,23 it cannot be assumed that findings regard-
ing Ca21 channels in rodent mast cells can be extrapolated to hu-
mans. In this study, we have therefore examined the expression
and function of CRACM channels in human lung mast cells
(HLMCs).METHODS
Full experimental details are provided in the Methods section in this arti-
cle’s Online Repository at www.jacionline.org.Human MC purification and cell culture
All human subjects gave written informed consent, and the study was
approved by the Leicestershire Research Ethics Committee. HLMCs were
purified from macroscopically normal human lung (n 5 11 donors) obtained
within 1 hour of resection for lung cancer as described previously.24 Final
HLMC purity was more than 99%, and viability was more than 97%. HLMCs
were cultured as described previously.25
The human MC line HMC-1 (a gift from Dr J. Butterfield, Mayo Clinic,
Rochester, Minn) was cultured in Iscove’s modified Dulbeccos’s medium as
described previously.24 HEK293 cells were cultured in Dulbeccomodified Ea-
gle medium (Invitrogen, Paisley, United Kingdom) containing 10% FCS.RT-PCR and quantitative RT-PCR
RT-PCR and quantitative RT-PCR were used to examine CRACM mRNA
expression in HLMCs. Full details including primer sequences are provided in
this article’s Online Repository at www.jacionline.org.Analysis of CRACM protein expression
Analysis of CRACM protein expression was undertaken by using Western
blot. Full experimental details and information on the antibodies used are
provided in this article’s Online Repository at www.jacionline.org.Patch-clamp electrophysiology
The whole-cell variant of the patch-clamp technique was used as described
previously.26 Currents in some experiments were also evoked by using a ramp
protocol consisting of a continuous voltage ramp from 2120 to 1120 mV.
Further details are provided in this article’s Online Repository at www.
jacionline.org.
The CRACM-channel blockers GSK-7975A and Synta-6627 (gifts from
GlaxoSmithKline, Stevenage, United Kingdom), Gd31, and La31were added
directly to the recording chamber as required. GSK-7975A is compound 36
from patent WO 2010/1222089.Ca21 imaging
Changes in intracellular-free Ca21 ([Ca21]i) were monitored fluoro-
metrically by use of the Ca21-sensitive probe Fura-2, as describedpreviously.8 Baseline measurements of HLMC [Ca21]i were recorded
as the mean of the 6 values preceding the addition of an anti-FcεRIa
antibody (Fisher Scientific, Loughborough, United Kingdom). The post-
activation value of [Ca21]i was recorded as the mean of the 6 recordings
taken immediately after the point of inflection following the rapid rise in
[Ca21]i.HLMC activation for mediator release
Experiments were performed at 378C. For the analysis of histamine and
LTC4 release, 2 3 10
4 HLMCs in 80 mL were added to a 96-well V-bottom
plate in triplicate, immediately followed by 10 mL of 10 times the final con-
centration of CRACM-channel blocker or dimethyl sulfoxide (DMSO) con-
trol. Plates were incubated for 10 minutes before the activation of cells by
the addition of 10 mL of 10 times anti-FcεRIa antibody (final dilution
1:300). Plates were incubated for 30 minutes and centrifuged, and the su-
pernatant was stored at 2208C for the measurement of mediator content.
Control cell pellets were lyzed in ultrapure water for the determination of
total histamine content. For the analysis of cytokine release, the final cell
concentration was 0.666 3 106 cells/mL, and IgE-sensitized cells were
activated with anti-IgE (Hybridoma Reagents Laboratory, Baltimore, Md;
final concentration 2 mg/mL) for 16 hours before harvesting the culture
supernatant.Mediator assays
Histamine was measured by radioenzymatic assay and LTC4 by ELISA as
described previously.24,26 The cytokines IL-5, IL-8, IL-13, and TNFa were
measured blind by using the Meso Scale Discovery platform.Allergen-induced bronchial smooth muscle
contraction in isolated human bronchus
Lung tissue was obtained postmortem. Airways were dissected free of lung
parenchyma and adjoining blood vessels. Secondary and tertiary bronchi, with
cartilaginous walls and diameters of 3 to 10 mm, were cut spirally into strips 3
to 5 mm wide and then cut into pieces 10 to 15 mm long. The strips were
passively sensitized overnight at room temperature (218C) in atopic serum
(20% v/v) in Krebs buffer. Before use, sensitized tissues were washed free of
serum. Tissues were mounted under 1.5 g of resting tension in an immersion
organ bath, maintained in oxygenated Krebs buffer solution at 378C, and
allowed to equilibrate for 30 to 45 minutes with 2 washes and retensioning if
required.
Two preliminary ‘‘priming’’ contractions to 10 mM methacholine (Sigma,
Poole, United Kingdom) were performed. The tissue was then incubated with
Synta-66 (10 mM) or DMSO control (0.1% final concentration) for 1 hour.
Grass allergen (Six grass mix, ALK-Abello, Hungerford, United Kingdom)
was then added cumulatively (0.1-30 U/mL final concentration), with
contractions measured in milligrams tension. This was followed by a final
measurement of contraction to 10 mMmethacholine. Data were expressed as
percentage of the initial 10 mM methacholine contraction.RESULTS
HMCs express CRACM1, -2, and -3 mRNAs
RT-PCR and quantitative RT-PCR experiments were per-
formed to determine the expression of CRACM-channel mRNAs
in HLMCs. Robust expression of CRACM1 (n 5 8 donors),
CRACM2 (n 5 6 donors), and CRACM3 (n 5 6 donors) was
observed in all donors examined and also inHMC-1 cells (Fig 1,A
and B). Normalizing the amount of each CRACM transcript to the
amount of either b-actin mRNA (Fig 1, C) or 18S RNA (data not
shown) revealed CRACM1 to be the most abundant of the 3
CRACM transcripts expressed in HLMCs. CRACM2 mRNA
was the least abundantly expressed, with levels of CRACM3
FIG 1. HLMCs express CRACM1, CRACM2, and CRACM3 mRNAs. RT-PCR
of CRACM1, -2, and -3 and rig/S15 mRNA transcripts using RNA purified
from HLMCs (A) and from HMC-1 cells (B) in the presence (1) or absence
(2) of reverse transcriptase. C, Quantitative RT-PCR of CRACM mRNA tran-
scripts in HLMCs relative to b-actin transcripts (mean 6 SEM; n 5 6-8).
CRACM1 versus CRACM2, P 5 .0068.
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tween CRACM1 and CRACM2 reached statistical significance
(P5 .0068; overall comparing all 3 transcripts: P5 .0299). Sim-
ilar relative amounts of CRACM transcripts were observed in
HMC-1 cells (data not shown).HLMCs express CRACM1 and -2 proteins
Western blotting of 3HLMC lysates from3 independent donors
revealed the presence of bands close to the predicted molecular
weight of CRACM1 (32.7 kDa) and CRACM2 (28.6 kDa) (Fig 2,
A). A blocking peptide for CRACM2 was available and inhibited
CRACM2 staining (Fig 2, B). Blotting for CRACM3 in HLMCs
failed to convincingly demonstrate the presence of band(s) close
to the predicted molecular weight of CRACM3 (31.5 kDa).
A higher molecular weight band was however identified (Fig 2,
C). The Western blotting of whole-cell lysates of HEK293 cells
transiently transfected with a construct directing the expression
of the myc epitope–tagged CRACM3 protein did reveal a band
of the expected size, indicating that the band identified in HLMCs
is likely to be nonspecific (Fig 2, D).HLMCs express CRACM currents following store
depletion with IP3
To investigate whether HLMCs expressed a Ca21 current in-
duced by store depletion, cells were dialyzed with 30 mM IP3.
This resulted in the development of an inwardly rectifying current
with the electrophysiological features of CRAC currents, the cur-
rent carried by CRACM channels (Fig 3, A) in 90% of the cells
tested. The subtracted IP3-dependent current (IP3 whole-cell cur-
rent minus baseline whole-cell current) peaked at a mean of 25.4
6 1.2 pA at 2120 mV with a reversal potential of 49.9 6 1.3
mV within 4 minutes of achieving the whole-cell configuration
(n 5 42 cells from 9 donors, P < .0001, compared with baseline
for both current and reversal potential) (Fig 3, A). The IP3-depen-
dent currentwas increased by32.06 3.2 pAby increasing extracel-
lular Ca21 to 10mM(n5 6 cells;P5.004) (Fig 3,B),with reversal
potential shifting to 59.6 6 4.4 mV (P 5 .009). Inspection of the
raw current obtained during voltage steps showed typical features
of CRACM channels with current evoked immediately following
each voltage step, and with mild decay over 100 ms (Fig 3, C).
Similar results were seen by using voltage ramps (data not shown).
Further pharmacological analysis of the current showed that it was
blocked dose dependently by GSK-7975A (IC50 of 3.4 3 10
27
mol/L) (Fig 3, D) and Synta-66 (IC50 of 2.5 3 10
27 mol/L)
(Fig 3,E). This is consistentwith the blocking ofCRACMchannels
by these compounds in previous studies27 (and unpublished data).
In addition, the IP3-induced current was blocked by 10 mM La
31
(Fig 3, F) and 10 mMGd31 (Fig 3, G), consistent with the proper-
ties of CRACM channels.17,22,28 CRACM currents did not develop
in control cells in the absence of IP3 (n5 9).HLMCs develop CRACM currents following
activation with anti-IgE
Cross-linking the high-affinity IgE receptor FcεRI with the
addition of anti-IgE to the recording chamber induced the
development of a current similar to that seen with IP3 in 90% of
the HLMCs tested (Fig 4, A). The subtracted IgE-dependent cur-
rent peaked at a mean of 18.96 1.5 pA at2120 mVwith a rever-
sal potential of 49.16 1.4 mV within 4 minutes of cell activation
(n 5 37 cells from 7 donors, P < .0001, compared with baseline
for both current and reversal potential). The current was increased
by 23.26 3.9 pA by increasing extracellular Ca21 to 10 mM (n5
7 cells; P 5 .003) (Fig 4, B), with a shift in reversal potential to
66.06 3.9 mV (P5 .005). Inspection of the raw current obtained
during voltage steps again showed typical features of CRACM
channels with current evoked immediately with each voltage
step and with mild decay over 100 ms (Fig 4, C). Similar results
were seen by using voltage ramps (data not shown). Further phar-
macological analysis of the IgE-dependent current showed it was
blocked by both 1 mMGSK-7975A (n5 5 cells; P5 .04) (Fig 4,
D) and 1 mM Synta-66 (n5 5 cells; P5 .0009) (Fig 4, E). In ad-
dition, the IgE-dependent current was blocked by 10 mM La31
(n 5 11; P 5 .0003) (Fig 4, F). Taken together, these findings
are consistent with the development of CRACM currents in
HLMCs following IgE-dependent activation.CRACM-channel blockers attenuate IgE-dependent
Ca21 influx in HLMCs
Activation of HLMCs with anti-FcεRIa induced an acute
increase in [Ca21]i followed by a plateau phase as described
FIG 2. HLMCs express CRACM1 and CRACM2 proteins. A, B, and C, Representative Western blots using the
indicated antibodies and lysates of HMC-1 and HLMCs (Fig 2, A and B) or A-20 cells and HLMCs (Fig 2, C).
Three independent mast cell lysates were analyzed. D,Western blots using the indicated antibodies and ly-
sates of HEK293 cells transiently transfected with vectors directing the expression of CRACM1-Myc (lane 1),
CRACM2-Myc (lane 2), or CRACM3-Myc (lane 3).
FIG 3. HLMCs express CRACM-channel currents when dialyzed with IP3. Subtracted whole-cell patch-clamp
current-voltage (I-V) curves from HLMCs 4 minutes after dialysis with IP3 in 2 mM external Ca
21 (mean 6
SEM; n 5 42 cells) (A) and in 2 mM and then 10 mM external Ca21 (mean 6 SEM; n 5 6) (B). C, Represen-
tative raw current traces from a single cell in the presence of IP3 (voltage protocol shown inset). Inhibition of
IP3-dependent whole-cell current by (D) GSK-7975A and (E) Synta-66 (n 5 4-6) (a negative value implies a
contribution from CRACM channels to the baseline whole-cell current) and (F) 10 mM La31 (n 5 12) and
(G) 10 mM Gd31.
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In the absence of CRACM-channel blockers, [Ca21]i increased
from a mean baseline of 164.9 6 9.0 to 375.6 6 17.4 nM (n 5
66 cells from 3 donors; P < .0001) following FcεRIa-dependent
activation. In HLMCs from matched donors, [Ca21]i increasedfrom a mean baseline of 191.7 6 16.4 to 287.0 6 25.7 nM
(n 5 52 cells from 3 donors; P < .0001) with 1 mM Synta-66.
There was a significant difference in the absolute change in
[Ca21]i in FcεRIa-activated control cells versus those activated
in the presence of Synta-66 (P < .0001). In summary, 1 mM
FIG 4. HLMCs express CRACM-channel currents following FcεRI-dependent activation. Whole-cell patch-
clamp current-voltage (I-V) curves of HLMCs within 4 minutes of FcεRI-dependent activation in (A) 2 mM ex-
ternal Ca21 (mean6 SEM; n5 37 cells) and (B) 2mM and then 10mM external Ca21 (mean6 SEM; n5 7). C,
Representative raw current following FcεRI-dependent activation. Inhibition of IgE-dependent CRACM cur-
rents by (D) 1 mM GSK-7975A, (E) 1 mM Synta-66, and (F) 10 mM La31 (n 5 11 cells). G, Attenuation of the
FcεRI-dependent increase in [Ca21]i in HLMCs by 1 mM Synta-66.
FIG 5. The CRACM-channel blockers GSK-7975A and Synta-66 inhibit
HLMC histamine (A), LTC4 (B), and cytokine release (C) dose-dependently
following FcεRI-dependent activation. Mean 6 SEM for percentage inhibi-
tion (n 5 5 for histamine and LTC , n 5 3 for cytokines). P < .05 for all con-
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54.8% 6 9.1%.
CRACM-channel blockers attenuate HLMC mediator
release
Following activation with anti-FcεRIa in the presence of
DMSO control, HLMCs released histamine (net 25.3% 6 4.8%
of total histamine content, a marker of degranulation), 125.7 6
32.5 ng/106 cells of LTC4 (a marker of arachidonic acid metabo-
lism), and IL-5 (505.16 142.7 pg/106 cells), IL-8 (88806 3469
pg/106 cells), IL-13 (140.5 6 78.7 pg/106 cells), and TNFa
(618.3 6 73.4 pg/106 cells). Both GSK-7975A and Synta-66
dose dependently attenuated the release of these mediators (P <
.05 by repeated-measures ANOVA for all drugs and mediators
with the exception of TNFa inhibition by Synta-66; P 5 .087)
(Fig 5, A-C). Net IgE-dependent histamine release was reduced
by 45.2% 6 2.5% (n 5 5; P < .0001) and 38.8% 6 5.4% (n 5
5; P < .0001) in the presence of 3 mM GSK-7975A and 3 mM
Synta-66, respectively. A similar degree of inhibition was seen
with the release of LTC4 (Fig 5, B) and the above cytokines
(Fig 5, C).4
ditions except Synta-66 TNFa analyzed by repeated-measures ANOVA on
raw data. *P < .05 compared with control using Bonferroni post hoc test.CRACM blockade attenuates allergen-induced
bronchial smooth muscle contraction in isolated
human bronchus
Allergen-induced bronchoconstriction was assessed in iso-
lated human bronchus. The application of allergen induced a
dose-dependent increase in bronchial smooth muscle contraction
(Fig 6) (geometric mean EC50 in DMSO control 0.825 [95% CI
0.50-1.35] grass allergen units/mL; maximal response 63.6% 6
4.1% of that induced by 10 mM methacholine; n 5 4). In thepresence of Synta-66 10 mM, there was a rightward shift in
the allergen dose-response curve (EC50 4.14 [95% CI 1.72-
9.96] grass allergen units/mL; P 5 .02). In 3 out of 4 experi-
ments, there was a marked reduction in the maximal response
(39.7% 6 7.0% of methacholine response for all data; P 5
.084). Synta-66 had no effect on methacholine-induced contrac-
tion (data not shown).
FIG 6. The CRACM-channel blocker Synta-66 attenuates allergen-dependent human bronchial smooth
muscle contraction (n 5 4). P 5 .02 for rightward shift in allergen EC50.
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In spite of the absolute requirement for an influx of extracel-
lular Ca21 for the FcεRI-dependent release of preformed
granule-derived mediators, newly generated leukotrienes and
prostaglandins, and many cytokines in human MCs, the Ca21
entry pathway has not been defined. Studies of knockout mice
lacking CRACM1 function have shown that CRACM channels
are essential for the influx of extracellular Ca21 into rodent
mast cells following their activation.22 In addition, indirect
evidence has implicated CRACM channels as the means of
Ca21 influx in human MCs derived from nasal polyps.29 Here
we show for the first time that HLMCs express CRACM1, -2,
and -3 at the mRNA level, at least CRACM1 and -2 at the pro-
tein level, and following IgE-dependent activation, functional
CRAC currents.
Our results are consistent with CRACMchannels playing a role
in the influx of extracellular Ca21 into HLMCs following their ac-
tivation. Two specific pharmacological blockers of CRACM
channels—GSK-7975A and Synta-6627—reduced the increase
in intracellular Ca21 that occurs following ligation of FcεRIa
and attenuated the release of histamine, LTC4, and several cyto-
kines. The inhibition by these drugs occurred in the dose range
of channel block demonstrated electrophysiologically. It takes ap-
proximately 5 to 10 times the IC50 of a channel blocker to inhibit
100% of the relevant channels. At 4 times the IC50, Synta-66 re-
duced FcεRI-dependent Ca21 influx by 50% and at 10 times the
IC50, both GSK-7975A and Synta-66 inhibited mediator release
by up to 50%.
The biological relevance of these findings with respect to
asthma is highlighted by the ability of Synta-66 to inhibit allergen-
induced bronchial smooth muscle contraction in ex vivo passively
sensitized bronchial tissue. The acute bronchoconstrictor smooth
muscle response to allergen challenge is entirely dependent on
the release of bronchospastic mediators from airway mast cells.30
In keeping with the attenuation of HLMC Ca21 influx and medi-
ator release observed with both Synta-66 and GSK-7975A,
Synta-66 shifted the dose-response curve for allergen-dependentbronchial smooth muscle contraction 5-fold to the right and mark-
edly reduced the maximal allergen-dependent response in 3 out of
4 donors. It should be noted that bronchial smoothmuscle cells ex-
press CRACM1 and demonstrate store-operated Ca21 currents,31
but it is unlikely that these currents in airway smooth muscle con-
tribute to allergen-induced bronchoconstriction induced by mast
cell mediators. This is because CRACM blockade had no effect
on bronchial smooth muscle contraction induced directly bymeth-
acholine, which means that it is unlikely that it would inhibit the
histamine and leukotriene-dependent contraction following
allergen-dependent mast cell degranulation. Thus, the highly re-
producible responses in both isolated HLMCs and tissue in the
presence of CRACM-channel blockers suggests that the predomi-
nant site of activity of the CRACM inhibition in tissue is the
mast cell.
Our results indicate that although important, CRACM chan-
nels may not be solely responsible for Ca21 influx into activated
HLMCs. The substantial residual histamine, LTC4, and cyto-
kine secretion that we observe using high concentrations of
blockers indicates that further Ca21-permeable channels and/
or receptors may play at least some role in Ca21 influx into
HLMCs. These results are in contrast to those from CRACM1
knockout mice where antigen-evoked Ca21 influx into mast
cells is reportedly reduced by 70% with the remaining Ca21 in-
flux being blocked by CRACM-channel inhibitors.22 Our results
therefore highlight further the heterogeneity of mast cells from
different species and underline the importance of studying hu-
man MCs rather than attempting to extrapolate results from ro-
dent mast cells.
In addition to CRACM, mast cells express a number of other
ion channels/receptors that may allow the entry of extracellular
Ca21. In rodents, the L-type voltage-gated Ca21 channel Cav1.2
may be involved in Ca21 influx independent of endoplasmic retic-
ulum Ca21 store emptying following mast cell activation.32 How-
ever, we have never observed a Cav-like current in HLMCs
although these cells do express mRNA for Cav3.3 and the a2d2
subunit.33 Our laboratory has also shown that HLMCs express
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as nonselective cation channels can produce significant Ca21 in-
flux in response to nucleotides such as ATP.34 Finally, much atten-
tion has been focused on the potential role of canonical transient
receptor potential channels in Ca21 entry following cell activation
that function as nonselective cation channels able to pass Ca21.
The potential role of all these channels will require further
investigation.
Our work provides strong evidence for the expression of both
CRACM1 and CRACM2, with CRACM1 transcripts present in
significantly higher amounts. To assess the contribution of each
channel to HLMC Ca21 entry will require the use of knockdown
strategies and the use of dominant negative mutants in future
work. In mouse mast cells CRACM1 dominates, while in mouse
T cells CRACM2 expression is the highest and CRACM1 is dis-
pensable for cell function.22 However, in human T cells,
CRACM1 is essential for cell function, and its complete absence
results in one form of hereditary severe combined immune defi-
ciency.17 Interestingly, while the expression of wild-type
CRACM1 in T cells from patients with severe combined immune
deficiency fully restores the CRAC current, expression of either
CRACM2 and/or CRACM3 is reported to have little or no ef-
fect,35 demonstrating that these channels have distinct roles.
Given the relative abundance of CRACM3 mRNA transcripts
in HLMCs, we were surprised not to be able to demonstrate
CRACM3 protein expression by Western blotting. It is possible
that CRACM3 is more sensitive to proteolysis than are its
homologs. Proteolysis has been noted as a problem in the analysis
of the protein expression of other mast cell ion channels.32 How-
ever, we have also been unable to demonstrate the expression of
CRACM3 by flow cytometry (data not shown), suggesting that
if it is expressed as a protein, it is expressed in relatively very
low amounts.
In conclusion, we have demonstrated the presence of functional
CRACM channels in HLMCs. Treatment of HLMCs with
CRACM-channel blockers reduced the release of mediators
and cytokines; CRACM channels are therefore a potential ther-
apeutic target in the treatment of asthma and related allergic
diseases.
Key messages
d The Ca21 influx pathway required for FcεRI-dependent
HLMC mediator release is not known.
d HLMCs express CRACM ion channels that contribute to
at least 50% of the Ca21 influx required for FcεRI-depen-
dent histamine, LTC4, and cytokine release, and allergen-
induced bronchial smooth muscle contraction.
d CRACM channels are a potential therapeutic target in the
treatment of asthma and related allergic diseases.
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Human mast cell purification and cell culture
All human subjects gave written informed consent, and the study was
approved by the Leicestershire Research Ethics Committee. HLMCs were
purified from macroscopically normal human lung (n 5 11 donors) obtained
within 1 hour of resection for lung cancer as described previously.E1 Final
HLMC purity was more than 99%, and viability was more than 97%. HLMCs
were cultured as described previously.E2 Cells were sensitized with human
myeloma IgE 2.5 mg/mL (Merck Bioscience Ltd, Nottingham, United King-
dom) as required.
The human MC line HMC-1 (a gift from Dr J. Butterfield, Mayo Clinic,
Rochester, Minn) was cultured in Iscove’s modified Dulbeccos’s medium (In-
vitrogen, Paisley, United Kingdom) as described previously.E1 HEK293 cells
were cultured in Dulbecco modified Eagle’s medium (Invitrogen) containing
10% FCS.
RT-PCR and quantitative RT-PCR
Total RNA was isolated from cells by using an RNAqueous-4PCR kit
(Applied Biosystems, Warrington, United Kingdom) according to the man-
ufacturer’s instructions. HMC-1 cells (1 mg) or HLMCs (0.4-1 mg) of total
RNAwas used to generate cDNA by using random decamer primers and a Ret-
roscript kit (Applied Biosystems). The following primer pairs were designed
to amplify channel cDNA: CRACM1 59GCCAGAGTTACTCCGAGGTG3 9
and 59TGACCGAGTTGAGATTGTGC3 9, CRACM2 59TCGACCCCTCTG
CTCCTGCC3 9 and 59TGCGGGGACTCGCTGATGGA3 9, and CRACM3
59TCGGCCACGTACCGGGAGTT39 and 59GCCCAGGGCAGTGGAGAA
GC3 9. The predicted product sizes were 311, 390, and 405 bp respectively.
Primers 59TTCCGCAAGTTCACCTACC3 9 and 59CGGGCCGGCCATGC
TTTACG3 9 designed to amplify a 361-bp sequence from the small ribosomal
subunit protein rig/S15 cDNAwere used as a positive control. Pfu DNA Pol-
ymerase (Promega, Southampton, United Kingdom) was used for the PCR
amplification.
For quantitative PCR, TaqMan probes for human CRACM1
(Hs00385627_m1), CRACM2 (Hs00259863_m1), and CRACM3
(Hs00752190_s1) were used together with TaqMan Gene Expression Master
Mix (all Applied Biosystems). Reactions were run on a Stratagene Mx3000P
(Agilent Technologies, Stockport, United Kingdom) real-time thermocycler.
For some HLMC donors, limiting amounts of RNA precluded the analysis of
CRACM1, -2, and -3 expression together in the same experiment. When this
was the case, expression of 2 of the 3 CRACM transcripts was analyzed.
Analysis of CRACM protein expression
Cells were lyzed in Radio-Immunoprecipitation Assay (RIPA) buffer (50
mM Tris HCl, pH 8.0, 150 mMNaCl, 1% NP-40, 0.5% sodium deoxycholate,
0.1% SDS) containing protease inhibitors. Proteins were separated on 12%
Bis-Tris Nu-Page gels (Invitrogen) and then blotted onto polyvinyidene
fluoride membranes. Membranes were blocked with 5% nonfat milk in PBS
and then probed with rabbit polyclonal antibodies recognizing CRACM1
(Alomone Labs Ltd, Jerusalem, Israel), CRACM2 (Alomone Labs Ltd),
CRACM3 (AbD Serotec, Kidlington, United Kingdom), or a mouse mono-
clonal anti-c-Myc antibody (clone 9E10, Sigma, Poole, United Kingdom). In
addition, the anti-CRACM2 antibody was used following preincubation with
its immunogenic (blocking) peptide. Blotswere subsequently probedwith goat
antirabbit immunoglobulins-horseradish peroxidise secondary antibody
(Dako, Cambridge, United Kingdom) or goat antimouse IgG-horseradish
peroxidise (Santa Cruz Biotechnology, Inc, Heidelberg, Germany) as appro-
priate. Immunoreactive bands were visualized by using Pierce ECLWestern
Blotting Substrate (Fisher Scientific, Loughborough, United Kingdom).
For the expression of c-Myc epitope–tagged CRACM channels, full-length
CRACM1 (accession no. NM_032790), CRACM2 (accession no.
NM_032831), and CRACM3 (accession no. NM_152288) were amplified
from cDNA generated from total RNA purified from a single HLMC donor us-
ing Pfu DNA polymerase. cDNAs were then cloned in frame immediately fol-
lowing the c-Myc epitope tag in vector pCruzMyc (Santa Cruz Biotechnology
Inc). HEK293 cells were transiently transfected with vectors directing the ex-
pression of c-Myc epitope–tagged CRACM channels using GeneJuicetransfection reagent (Merck Bioscience Ltd) and harvested for lysis 24 hours
after transfection.
Patch-clamp electrophysiology
The whole-cell variant of the patch-clamp technique was used.E3,E4 Patch
pipettes were made from borosilicate fiber-containing glass (Clark Electro-
medical Instruments, Reading, United Kingdom), and their tips were heat pol-
ished, typically resulting in resistances of 4 to 6 MU. The standard pipette
solution contained CsCl (140 mM), MgCl2 (2 mM), HEPES (10 mM), NaATP
(2 mM), and GTP (0.1 mM), pH 7.3, with KOH. For IP3 experiments, 5 mM
EGTA was also added to the pipette solution. For anti-IgE experiments,
intracellular Ca21 was buffered to 250 nM by using CaCl2 and ethylenegly-
col-bis-(b-aminoethylether)-N,N,N9,N9-tetraacetic acid. The standard exter-
nal solution contained NaCl (140 mM), KCl (5 mM), CaCl2 (2 mM), MgCl2
(1 mM), HEPES (10 mM), and glucose (5 mM), pH 7.3, with NaOH. For re-
cording, mast cells were placed in 35-mm dishes containing standard external
solution.
Whole-cell currents were recorded by using an Axoclamp 200A amplifier
(Axon Instruments, FosterCity, Calif), and currents usually evokedby applying
voltage commands to a range of potentials in 10-mV steps from a holding
potential of220mV. The currents were digitized (sampled at a frequency of 10
kHz), stored on computer, and subsequently analyzed by using pClamp
software (Axon Instruments). Capacitance transients were minimized by using
the capacitance neutralization circuits on the amplifier. Correction for series
resistance was not routinely applied. Experiments were performed at 278C,
temperature being controlled by a Peltier device. Experiments were performed
with a perfusion system (Automate Scientific, Inc, San Francisco, Calif) to
allow solution changes, although drugs were added directly to the recording
chamber. Currents in some experiments were also evoked by using a ramp
protocol consisting of a continuous voltage ramp from 2120 to 1120 mV.
The CRACM-channel blockers GSK-7975A and Synta-66E5 (gifts from
GlaxoSmithKline, Stevenage, United Kingdom), Gd31 (gadolinium(III) chlo-
ride), and La31 (lanthanum(III) chloride) were added directly to the recording
chamber as required. GSK-7975A is compound 36 from patent WO 2010/
1222089.
Ca21 imaging
Changes in [Ca21]i were monitored fluorometrically by use of the Ca
21-
sensitive probe Fura-2. Cells were loaded with Fura-2 (Molecular Probes, Eu-
gene, Ore) by incubation in normal physiological saline solution (130 mM
NaCl, 5.6 mM KCl, 1 mM MgCl2, 2 mM CaCl2, 11 mM glucose, 10 mM
HEPES, pH 7.4, with NaOH) containing 2 mM fura-2-acetoxymethyl ester
(Fura-2-AM) for 30 minutes at room temperature and then washed for 30min-
utes. A coverslip with attached cells was mounted in a perfusion chamber at
378C. The single-cell recording system has been described previously.E2
Data acquisition occurred at a rate of one dual-wavelength image every 6 sec-
onds as the 340/380 nm ratio. This was converted to [Ca21]i by using a com-
mercially available calibration kit (Molecular Probes). Drugs were added to
the dish as required. Baseline measurements of HLMC [Ca21]i were recorded
as the mean of the 6 values preceding the addition of an anti-FcεRIa antibody
(Fisher Scientific). The postactivation value of [Ca21]i was recorded as the
mean of the 6 recordings taken immediately after the initial peak.
HLMC activation for mediator release
Experiments were performed at 378C. For the analysis of histamine and
leukotriene release, 23 104 HLMCs in a volume of 80mLwere added to a 96-
well V-bottom plate in triplicate, immediately followed by 10 mL of 10 times
the final concentration of CRACM-channel blocker or DMSO control. Plates
were incubated for 10 minutes before the activation of cells by the addition of
10 mL of 10 times anti-FcεRIa antibody (final dilution of antibody 1:300).
Plates were incubated for 30 minutes and centrifuged, and the supernatant
was decanted and stored at 2208C for the measurement of mediator content.
Control cell pellets were lyzed in ultrapurewater for the determination of total
histamine content.
For the analysis of cytokine release, the final cell concentration was
0.666 3 106 cells/mL, and IgE-sensitized cells were activated with anti-IgE
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Mediator assays
Histamine was measured by radioenzymatic assay and LTC4 by ELISA as
described previously.E1,E4 The cytokines IL-5, IL-8, IL-13, and TNFa were
measured by using a human TH1/TH2 multiplex plate on a Sector Imager
6000 (Meso Scale Discovery, Gaithersburg, Md).
Allergen-induced bronchial smooth muscle
contraction in isolated human bronchus
Lung tissue was obtained postmortem. Airways were dissected free of lung
parenchyma and adjoining blood vessels. Secondary and tertiary bronchus,
with cartilaginous walls and diameters of 3 to 10 mm, were cut spirally into
strips approx 3 to 5 mm wide and then cut into pieces approximately 10 to 15
mm long. The strips were then passively sensitized overnight at room
temperature (218C) in atopic serum (20% v/v) in Krebs buffer. Before use,
sensitized tissues were washed free of serum. Tissues were mounted under 1.5
g of resting tension in an immersion organ bath, maintained in oxygenated
Krebs buffer solution at 378C, and allowed to equilibrate for 30 to 45 minutes
with 2 washes and retensioning if required.
Two preliminary ‘‘priming’’ contractions to 10 mM methacholine (Sigma,
Poole, United Kingdom) were performed. The tissue was then incubated withSynta-66 (10 mM) or DMSO control (0.1% final concentration) for 1 hour.
Grass allergen (Six grass mix, Alk-Abello, Hungerford, United Kingdom)was
then added (0.1-30 U/mL final concentration), with contractions measured in
milligrams tension. This was followed by the measurement of contraction to
10 mM methacholine. Data were expressed as % of the initial 10 mM
methacholine contraction. Only limited quantities of viable human bronchus
tissue were available, which allowed examination of the effects of only a
single CRACM-channel blocker.
